Short answer
Monte Rosa Therapeutics, Inc. (GLUE) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results announced for quarter ended June 30, 2026.
Monte Rosa Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results announced for quarter ended June 30, 2026
- Full earnings release furnished as Exhibit 99.1, containing the detailed results and management commentary
Item EX-99.1 · Exhibit EX-99.1
- Q2 2026 net loss $43.4M vs $12.3M, reflecting R&D investment rising to $48.0M from $30.7M
- Cash, restricted cash and marketable securities $626.0M, supporting operations into 2029 despite $45.2M quarterly decline
- MRT-8102 GFORCE-1 fully enrolled, with readout anticipated in H2 2026 and 85% median CRP reduction after four weeks
- Multiple MRT-8102 Phase 2 launches planned through H1 2027 across cardiovascular risk, gout and hidradenitis suppurativa
- Novartis activated MRT-6160 Sjögren’s Phase 2, triggering a milestone opportunity within potential $2.1B total payments
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Monte Rosa Therapeutics, Inc. 8-K filings
Get the next GLUE 8-K as it lands
Follow GLUE for push alerts, or ask the research agent what this filing means.